UZ Brussel
Laarbeeklaan 101, Jette, Brussels Capital, 1090, Belgium
Overview
UZ Brussel is a university hospital. This means that it also has a teaching mission and conducts scientific research. The hospital’s clinical excellence, scientific commitment and human-centric tuition ensure the highest degree of competence in many fields. The hospital is closely associated with the Vrije Universiteit Brussel (Free University Brussels), notably the Medicine and Pharmacy Faculties. As a top-rate hospital, UZ Brussels has gained recognition at national and international level. With its 700 beds, each year UZ Brussel admits more than 25,000 patients and treats 400,000 outpatients, both national and international. The values of UZ Brussel reflect one single objective: to provide patients with the best possible care. Your care is our care.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 2
Sector focus
- Health Care
- Hospital
- Universities
Investment portfolio
- Abscint
Participated · Equity · May 2021
ABSCINT is a clinical-stage molecular imaging company and VUB spin-off developing radiopharmaceutical diagnostics using single-domain antibodies for fast, whole-body visualization of molecular markers. The company has two clinical-stage programs: ABSCINT-HER2 for detecting HER2 cancers (including HER2-low and HER2-positive) and ABSCINT-206 for detecting cardiac sarcoidosis. Its technology is based on joint research from teams at VUB and the VIB-VUB Center for Inflammation Research. ABSCINT’s diagnostics are intended for disease diagnosis, treatment selection, and monitoring treatment response. The company announced a new financing that provides an additional €1.0M in capital. New and existing investors are positioned to support continued development of its two radiopharmaceutical programs. ABSCINT is developing single-domain antibody-based radiopharmaceutical diagnostics that enable rapid targeting and visualization of specific molecular markers across the whole body via PET scans. Its lead program, ABSCINT-HER2, is designed to map HER2 expression across cancer lesions and address tumour heterogeneity to improve selection for HER2-targeted therapies. The company has clinical-stage programs in both oncology and cardiovascular diseases. ABSCINT plans to initiate Phase II clinical trials for ABSCINT-HER2 to evaluate detection of HER2 heterogeneity in metastatic breast cancer. Financially, the company secured an additional €3 million from a syndicate of investors to support these clinical activities. Koen Dewaele will take the position of chairman of ABSCINT’s board and is joining as a private investor to support the company’s development.